Investigational drug · Phase 2
Progerinin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Werner Syndrome, Hutchinson-Gilford Progeria Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Progerinin"
First trial start
2025
Jan 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Progerinin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Werner Syndrome
- Hutchinson-Gilford Progeria Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Progerinin" as an intervention, largest first.
PRG Science & Technology Co., Ltd.Industry
NCT04512963 · 64 participants · Start Aug 24, 2020 · Primary completion Jul 27, 2021
Drug: Progerinin; Placebo · For: Hutchinson-Gilford Progeria Syndrome; Werner Syndrome
Sites: Glendale, California
PRG Science & Technology Co., Ltd.Industry
NCT06775041 · 10 participants · Start Jan 13, 2025 · Primary completion Mar 30, 2026
Drug: Progerinin; Lonafarnib · For: Hutchinson-Gilford Progeria Syndrome
Sites: Boston, Massachusetts
- Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner SyndromeRecruiting
PRG Science & Technology Co., Ltd.Industry
NCT05847179 · 5 participants (planned) · Start Oct 2026 · Primary completion Dec 2027
Drug: Progerinin · For: Werner Syndrome
Sites: Ann Arbor, Michigan
Newest research
PubMed records naming it or its code names, newest first.
- Author Correction: Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.
Kang SM, Yoon MH, Ahn J, et al. · Commun Biol 2026
- Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.
Kang SM, Seo S, Song EJ, et al. · Cells 2023
- Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A.
Kang SM, Yoon MH, Lee SJ, et al. · Sci Rep 2021
- Author Correction: Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.
Kang SM, Yoon MH, Ahn J, et al. · Commun Biol 2021
- Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.
Kang SM, Yoon MH, Ahn J, et al. · Commun Biol 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.